References
- Julicher P, Galli C. Identifying cost-effective screening algorithms for active hepatitis C virus infections in a high prevalence setting. J Med Econ. 2018;21(1):1–10. doi:10.1080/13696998.2017.1369983
- Nguyen LT, Gray E, O’Leary A, Carr M, De Gascun CF; Irish Hepatitis CORN. The role of hepatitis c virus core antigen testing in the era of direct acting antiviral therapies: what we can learn from the protease inhibitors. PLoS One. 2016;11(10):e0163900. doi:10.1371/journal.pone.0163900
- Feng B, Yang RF, Jiang HJ, et al. Correlation analysis of hepatitis C virus core antigen and low viral loads: can core antigen replace nucleic acid test? Clin Exp Med. 2020;20(1):131–141. doi:10.1007/s10238-019-00588-1
- Takahashi K, Okamoto H, Kishimoto S, et al. Demonstration of a hepatitis C virus-specific antigen predicted from the putative core gene in the circulation of infected hosts. J Gen Virol. 1992;73(3):667–672. doi:10.1099/0022-1317-73-3-667
- Freiman JM, Tran TM, Schumacher SG, et al. Hepatitis C core antigen testing for diagnosis of hepatitis c virus infection: a systematic review and meta-analysis. Ann Intern Med. 2016;165(5):345–355. doi:10.7326/M16-0065
- Chang C, Hung CH, Wang JH, Lu SN. Hepatitis C core antigen highly correlated to HCV RNA. Kaohsiung J Med Sci. 2018;34(12):684–688. doi:10.1016/j.kjms.2018.08.002
- Cetiner S, Cetin Duran A, Kibar F, Yaman A. Performance comparison of new generation HCV core antigen test versus HCV RNA test in management of hepatitis C virus infection. Transfus Apher Sci. 2017;56(3):362–366. doi:10.1016/j.transci.2017.02.005
- Lamoury FMJ, Hajarizadeh B, Soker A, et al. Evaluation of a hepatitis C virus core antigen assay in plasma and dried blood spot samples. J Mol Diagn. 2018;20(5):621–627. doi:10.1016/j.jmoldx.2018.05.010
- Bartels DJ, Sullivan JC, Zhang EZ, et al. Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment. J Virol. 2013;87(3):1544–1553. doi:10.1128/JVI.02294-12
- World Health Organization. Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection. Geneva: World Health Organization; 2018. Available from: https://www.who.int/hepatitis/publications/hepatitis-c-guidelines-2018/en/. Accessed June 13, 2022.
- Ghany MG, Morgan TR, Panel A-IHCG. Hepatitis C guidance 2019 update: American association for the study of liver diseases-infectious diseases society of America recommendations for testing, managing, and treating hepatitis C virus infection. Hepatology. 2020;71(2):686–721. doi:10.1002/hep.31060
- De Paschale M, Manco MT, Arpino O, et al. Threshold value of LIAISON XL anti-HCV screening assay predicting positive immunoblotting results. J Med Virol. 2017;89(10):1817–1822. doi:10.1002/jmv.24831
- Liu Z, Mao X, Wu J, et al. World-wide prevalence of substitutions in HCV genome associated with resistance to direct-acting antiviral agents. Clin Gastroenterol Hepatol. 2019;19(9):1906–1914.
- Sarrazin C, Dvory-Sobol H, Svarovskaia ES, et al. Prevalence of resistance-associated substitutions in HCV NS5A, NS5B, or NS3 and outcomes of treatment with ledipasvir and sofosbuvir. Gastroenterology. 2016;151(3):501–512. doi:10.1053/j.gastro.2016.06.002
- Chen Q, Perales C, Soria ME, et al. Deep-sequencing reveals broad subtype-specific HCV resistance mutations associated with treatment failure. Antiviral Res. 2020;174:104694. doi:10.1016/j.antiviral.2019.104694
- Han B, Martin R, Xu S, et al. Sofosbuvir susceptibility of genotype 1 to 6 HCV from DAA-naive subjects. Antiviral Res. 2019;170:104574. doi:10.1016/j.antiviral.2019.104574